Skip to main content

Sidney Hillman Health Center o v. Abbott Laboratories, Incorpora

7th CircuitOctober 12, 2017No. 17-1483Cited 15 times
Defendant WinAbbott Laboratories
Facing something similar at work?Check your rights — free, private, no sign-up

Case Details

Judge(s)
Easterbrook, Kanne, Williams
Status — whether other courts must follow this ruling
Published
Procedural Posture — the stage the case had reached
appeal

Related Laws

No specific laws identified for this ruling.

Outcome

The Seventh Circuit affirmed dismissal of the plaintiffs' civil RICO suit against Abbott Laboratories, holding that the welfare-benefit plan payors lacked standing as the directly injured parties and could not establish proximate causation because patients—not payors—were the primary victims of the unlawful off-label drug promotion scheme.

What This Ruling Means

**Abbott Laboratories Wins Case Over Drug Marketing Claims** Sidney Hillman Health Center and other employee benefit plans sued Abbott Laboratories, claiming the pharmaceutical company illegally promoted drugs for uses not approved by the FDA. The health plans argued this cost them money because they had to pay for expensive treatments that weren't properly tested or approved for those specific uses. The court dismissed the case entirely. The appeals court ruled that the employee benefit plans couldn't sue because they weren't the ones directly harmed by Abbott's actions. Instead, the court said patients who received the medications were the primary victims, not the insurance plans that paid for them. The court also found that any connection between Abbott's marketing and the health plans' financial losses was too indirect to support a lawsuit. This ruling matters for workers because it shows how difficult it can be for employee benefit plans to recover money when they believe pharmaceutical companies have acted improperly. When health insurance costs rise due to questionable drug marketing, workers and their employers may have limited legal options to get that money back, even if the drug company's conduct was problematic.

This summary was generated to explain the ruling in plain English and is not legal advice.

Browse Related

Facing something similar at work?

Court rulings like this one are useful, but every situation is different. Take 2 minutes to see which laws may protect you — it's free, private, and no account is required to start.

This ruling information is sourced from public court records via CourtListener.com. Case outcomes, claim types, and summaries are extracted using AI analysis and may be incomplete or inaccurate. It is provided for informational and educational purposes only and does not constitute legal advice.

See something wrong, or named in this ruling and want it corrected or redacted? Request a correction.